|
Name
|
2H-Imidazol-2-one, 1-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-4-methyl-2H-pyrazolo[4,3-c]pyridin-3-yl]-3-(4-fluoro-1-methyl-1H-indazol-5-yl)-1,3-dihydro-, (4S)-;
|
|---|---|
|
Synonyms
|
(2H-Imidazol-2-one, 1-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-4-methyl-2H-pyrazolo[4,3-c]pyridin-3-yl]-3-(4-fluoro-1-methyl-1H-indazol-5-yl)-1,3-dihydro-;
(S)-1-(4-Fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one;
(S)-1-(4-Fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one;
Orfiril Intermediate;
5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2-(4-fluoro-3,5-dimethylphenyl)-3-[4-fluoro-1-methyl-1H-indazol-5-yl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-2,4,6,7-tetrahydro-4-methyl-, (1S,2R)-;
(1S,2R)-1-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl-1H-indol-1-yl)-2-methylcyclopropyl-1,2,4-oxadiazol-5(4H)-one
|
|
CAS
|
2212022-56-3
|
|
MF
|
C₂₆H₂₅F₂N₇O
|
|
MW
|
489.52
|
|
Boiling Point
|
650.0 ± 65.0 °C (Predicted)
|
|
Density
|
1.45 ± 0.1 g/cm³ (Predicted)
|
|
Acid Dissociation Constant (pKa)
|
8.39 ± 0.40 (Predicted)
|
|
Usage
|
Key Precursor for Oglemilast API Synthesis: As a critical intermediate for synthesizing Oglemilast, a phosphodiesterase-4 (PDE4) inhibitor, it constructs the core heterocyclic scaffold of the final drug through specific cyclization and functional group modification reactions, directly determining the pharmacological activity and product purity of Oglemilast. R&D Template for Analogous PDE4 Inhibitors: Its fluorine-containing heterocycles (indazole ring, pyrazolopyridine ring) and chiral structure serve as a structural template for developing novel PDE4 inhibitors. It is used to optimize the anti-inflammatory activity, metabolic stability, and tolerability of drugs, expanding the R&D direction of therapeutic agents for inflammatory airway diseases. Reference Building Block for Complex Heterocyclic Drug Synthesis: Containing multiple fused heterocycles, chiral centers, and typical fluorine-substituted structures, it acts as a reference building block for the synthesis of complex heterocyclic drugs. It provides structural reference and synthetic ideas for designing and synthesizing bioactive molecules with similar scaffolds (e.g., antibacterial and antitumor drugs).
|
Hot Tags: cas：2212022-56-3 orforglipron intermediate a, China, manufacturers, suppliers, factory, custom, wholesale
